Citations

Clear

3942 citation(s) found for "To, Van".

Invasive Right Ventricular Pressure-Volume Analysis: Basic Principles, Clinical Applications, and Practical Recommendations
Brener, Michael I. , Masoumi, Amirali, Ng, Vivian G., Tello, Khodr , Bastos, Marcelo B. , Cornwell, William K. , Hsu, Steven , Tedford, Ryan J. , Lurz, Philipp , Rommel, Karl-Philipp , Kresoja, Karl-Patrik , Nagueh, Sherif F. , Kanwar, Manreet , Kapur, Navin K. , Hiremath, Gurumurthy , Sarraf, Mohammad, Enden, Antoon J.M. Van Den, Heerdt, Paul M., Kodali, Susheel K., Uriel, Nir , Kanwar, Manreet K , Van Mieghem, Nicolas M , Hahn, Rebecca T , Sayer, Gabriel T , Uriel, Nir , Burkhoff, Daniel , Lurz, Philipp , Tedford, Ryan J , Brener, Michael I. , Masoumi, Amirali, Ng, Vivian G., Tello, Khodr , Bastos, Marcelo B. , Cornwell, William K. , Hsu, Steven , Rommel, Karl-Philipp , Kresoja, Karl-Patrik , Nagueh, Sherif F. , Kapur, Navin K , Hiremath, Gurumurthy , Sarraf, Mohammad, Enden, Antoon J.M. Van Den, Heerdt, Paul M., Kodali, Susheel K.

Mayo Clinic

Circulation: Heart Failure | December 29, 2021 | Volume: 15 | Issue: 1 | Pages: No page available

10.1161/circheartfailure.121.009101 | PMID 34963308 Get It

Right ventricular pressure-volume (PV) analysis characterizes ventricular systolic and diastolic properties independent of loading conditions like volume status and afterload. While long-considered the gold-standard method for quantifying myocardial chamber performance, it was traditionally only performed in highly specialized research settings. With recent advances in catheter technology and more sophisticated approaches to analyze PV data, it is now more commonly used in a variety of clinical and research settings. Herein, we review the basic techniques for PV loop measurement, analysis, and interpretation with the aim of providing readers with a deeper understanding of the strengths and limitations of PV analysis. In the second half of the review, we detail key scenarios in which right ventricular PV analysis has influenced our understanding of clinically relevant topics and where the technique can be applied to resolve additional areas of uncertainty. All told, PV analysis has an important role in advancing our understanding of right ventricular physiology and its contribution to cardiovascular function in health and disease.
Therapeutic endoscopic ultrasound: European Society of Gastrointestinal Endoscopy (ESGE) Guideline
Merwe, Van der , Wanrooij, Roy L.J. van , Bronswijk, Michiel , Rimbaș, Mihai , Hucl, Tomáš , Kunda, Rastislav , Badaoui, Abdenor , Law, Ryan , Arcidiacono, Paolo Giorgio , Larghi, Alberto , Giovannini, Marc, Khashab, Mouen A. , Binmoeller, Kenneth F., Hooft, Jeanin E. van , van Wanrooij, Roy L J , Rimbas, Mihai , Kunda, Rastislav , Barthet, Marc , Perez-Miranda, Manuel , van Hooft, Jeanin E , Arcidiacono, Paolo Giorgio , Everett, Simon M , Lakhtakia, Sundeep , Pérez‐Miranda, Manuel

Mayo Clinic

Endoscopy | December 22, 2021 | Volume: 54 | Issue: 02 | Pages: 185-205

10.1055/a-1717-1391 | PMID 34937098 Get It

Main Recommendations 1 ESGE recommends the use of endoscopic ultrasound-guided biliary drainage (EUS-BD) over percutaneous transhepatic biliary drainage (PTBD) after failed endoscopic retrograde cholangiopancreatography (ERCP) in malignant distal biliary obstruction when local expertise is available. Strong recommendation, moderate quality evidence. 2 ESGE suggests EUS-BD with hepaticogastrostomy only for malignant inoperable hilar biliary obstruction with a dilated left hepatic duct when inadequately drained by ERCP and/or PTBD in high volume expert centers. Weak recommendation, moderate quality evidence. 3 ESGE recommends that EUS-guided pancreatic duct (PD) drainage should only be considered in symptomatic patients with an obstructed PD when retrograde endoscopic intervention fails or is not possible. Strong recommendation, low quality evidence. 4 ESGE recommends rendezvous EUS techniques over transmural PD drainage in patients with favorable anatomy owing to its lower rate of adverse events. Strong recommendation, low quality evidence. 5 ESGE recommends that, in patients at high surgical risk, EUS-guided gallbladder drainage (GBD) should be favored over percutaneous gallbladder drainage where both techniques are available, owing to the lower rates of adverse events and need for re-interventions in EUS-GBD. Strong recommendation, high quality of evidence. 6 ESGE recommends EUS-guided gastroenterostomy (EUS-GE), in an expert setting, for malignant gastric outlet obstruction, as an alternative to enteral stenting or surgery. Strong recommendation, low quality evidence. 7 ESGE recommends that EUS-GE may be considered in the management of afferent loop syndrome, especially in the setting of malignancy or in poor surgical candidates. Strong recommendation, low quality evidence. 8 ESGE suggests that endoscopic ultrasound-directed transgastric ERCP (EDGE) can be offered, in expert centers, to patients with a Roux-en-Y gastric bypass following multidisciplinary decision-making, with the aim of overcoming the invasiveness of laparoscopy-assisted ERCP and the limitations of enteroscopy-assisted ERCP. Weak recommendation, low quality evidence.
Cardiovascular magnetic resonance-derived left ventricular intraventricular pressure gradients among patients with precapillary pulmonary hypertension
Vos, Jacqueline L , Leiner, Tim , Alenezi, Fawaz , Rodwell, Laura , Wegen, Constantijn T P M van der, Post, Marco C. , Driessen, M. M. P. , Nijveldt, Robin , Driessen, Mieke M P, Nijveldt, Robin , Leiner, Tim , Dijk, Arie P.J. van , Pedrizzetti, Gianni , Rodwell, Laura

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | December 22, 2021 | Volume: 24 | Issue: 1 | Pages: 78-87

10.1093/ehjci/jeab294 | PMID 34993533 Get It

Abstract Aims Precapillary pulmonary hypertension (pPH) affects left ventricular (LV) function by ventricular interdependence. Since LV ejection fraction (EF) is commonly preserved, LV dysfunction should be assessed with more sensitive techniques. Left atrial (LA) strain and estimation of LV intraventricular pressure gradients (IVPG) may be valuable in detecting subtle changes in LV mechanics; however, the value of these techniques in pPH is unknown. Therefore, the aim of our study is to evaluate LA strain and LV-IVPGs from cardiovascular magnetic resonance (CMR) cines in pPH patients. Methods and results In this cross-sectional study, 31 pPH patients and 22 healthy volunteers underwent CMR imaging. Feature-tracking LA strain was measured on four- and two-chamber cines. LV-IVPGs (from apex–base) are computed from a formulation using the myocardial movement and velocity of the reconstructed 3D-LV (derived from long-axis cines using feature-tracking). Systolic function, both LV EF and systolic ejection IVPG, was preserved in pPH patients. Compared to healthy volunteers, diastolic function was impaired in pPH patients, depicted by (i) lower LA reservoir (36 ± 7% vs. 26 ± 9%, P < 0.001) and conduit strain (26 ± 6% vs. 15 ± 8%, P < 0.001) and (ii) impaired diastolic suction (−9.1 ± 3.0 vs. ‒6.4 ± 4.4, P = 0.02) and E-wave decelerative IVPG (8.9 ± 2.6 vs. 5.7 ± 3.1, P < 0.001). Additionally, 11 pPH patients (35%) showed reversal of IVPG at systolic–diastolic transition compared to none of the healthy volunteers (P = 0.002). Conclusions pPH impacts LV function by altering diastolic function, demonstrated by an impairment of LA phasic function and LV-IVPG analysis. These parameters could therefore potentially be used as early markers for LV functional decline in pPH patients.
Encephalocele‐associated temporal lobe epilepsy and skull fibrous dysplasia: a report of two cases
Cox, Benjamin C. , Jones, Ojore O., Smith, Kelsey M. , Kotsenas, Amy L. , Gompel, Jamie J. Van , Burkholder, David B. , Wong‐Kisiel, Lily C.

Mayo Clinic

Epileptic Disorders | December 22, 2021 | Volume: 23 | Issue: 6 | Pages: 940-943

10.1684/epd.2021.1335 | PMID 34668858 Get It

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
Vogelbaum, Michael A. , Brown, Paul D. , Messersmith, Hans , Brastianos, Priscilla K. , Burri, Stuart H., Dunn, Ian F. , Gaspar, Laurie E., Gatson, Na Tosha , Gondi, Vinai , Lassman, Andrew B. , Maués, Julia , Mohile, Nimish, Redjal, Navid , Stevens, Glen , Bent, Martin J. van den , Wallace, H. James , Weinberg, Jeffrey S. , Zadeh, Gelareh , Schiff, David , van den Bent, Martin J , Gatson, Na Tosha N , Redjal, Navid , Messersmith, Hans , Cahill, Daniel P. , Jordan, Justin T. , Sulman, Erik P.

Mayo Clinic

Neuro-Oncology | December 21, 2021 | Volume: 24 | Issue: 3 | Pages: 331-357

10.1093/neuonc/noab262 Get It

Abstract Purpose To provide guidance to clinicians regarding therapy for patients with brain metastases from solid tumors. Methods ASCO convened an Expert Panel and conducted a systematic review of the literature. Results Thirty-two randomized trials published in 2008 or later met eligibility criteria and form the primary evidentiary base. Recommendations Surgery is a reasonable option for patients with brain metastases. Patients with large tumors with mass effect are more likely to benefit than those with multiple brain metastases and/or uncontrolled systemic disease. Patients with symptomatic brain metastases should receive local therapy regardless of the systemic therapy used. For patients with asymptomatic brain metastases, local therapy should not be deferred unless deferral is specifically recommended in this guideline. The decision to defer local therapy should be based on a multidisciplinary discussion of the potential benefits and harms that the patient may experience. Several regimens were recommended for non–small-cell lung cancer, breast cancer, and melanoma. For patients with asymptomatic brain metastases and no systemic therapy options, stereotactic radiosurgery (SRS) alone should be offered to patients with one to four unresected brain metastases, excluding small-cell lung carcinoma. SRS alone to the surgical cavity should be offered to patients with one to two resected brain metastases. SRS, whole brain radiation therapy, or their combination are reasonable options for other patients. Memantine and hippocampal avoidance should be offered to patients who receive whole brain radiation therapy and have no hippocampal lesions and 4 months or more expected survival. Patients with asymptomatic brain metastases with either Karnofsky Performance Status ≤ 50 or Karnofsky Performance Status < 70 with no systemic therapy options do not derive benefit from radiation therapy. Additional information is available at www.asco.org/neurooncology-guidelines.
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
Vogelbaum, Michael A. , Brown, Paul D. , Messersmith, Hans , Brastianos, Priscilla K. , Burri, Stuart H., Dunn, Ian F. , Gaspar, Laurie E., Gatson, Na Tosha , Gondi, Vinai , Jordan, Justin T. , Lassman, Andrew B. , Maués, Julia , Mohile, Nimish, Redjal, Navid , Stevens, Glen , Bent, Martin J. van den , Wallace, H. James , Weinberg, Jeffrey S. , Zadeh, Gelareh , Schiff, David , Gatson, Na Tosha N , Jordan, Justin T , Lassman, Andrew B , Maues, Julia , Redjal, Navid , Stevens, Glen , Sulman, Erik P , van den Bent, Martin J , Wallace, H James , Messersmith, Hans , Cahill, Daniel P. , Sulman, Erik P.

Mayo Clinic

Journal of Clinical Oncology | December 21, 2021 | Volume: 40 | Issue: 5 | Pages: 492-516

10.1200/jco.21.02314 | PMID 34932393 Get It

PURPOSE To provide guidance to clinicians regarding therapy for patients with brain metastases from solid tumors. METHODS ASCO convened an Expert Panel and conducted a systematic review of the literature. RESULTS Thirty-two randomized trials published in 2008 or later met eligibility criteria and form the primary evidentiary base. RECOMMENDATIONS Surgery is a reasonable option for patients with brain metastases. Patients with large tumors with mass effect are more likely to benefit than those with multiple brain metastases and/or uncontrolled systemic disease. Patients with symptomatic brain metastases should receive local therapy regardless of the systemic therapy used. For patients with asymptomatic brain metastases, local therapy should not be deferred unless deferral is specifically recommended in this guideline. The decision to defer local therapy should be based on a multidisciplinary discussion of the potential benefits and harms that the patient may experience. Several regimens were recommended for non–small-cell lung cancer, breast cancer, and melanoma. For patients with asymptomatic brain metastases and no systemic therapy options, stereotactic radiosurgery (SRS) alone should be offered to patients with one to four unresected brain metastases, excluding small-cell lung carcinoma. SRS alone to the surgical cavity should be offered to patients with one to two resected brain metastases. SRS, whole brain radiation therapy, or their combination are reasonable options for other patients. Memantine and hippocampal avoidance should be offered to patients who receive whole brain radiation therapy and have no hippocampal lesions and 4 months or more expected survival. Patients with asymptomatic brain metastases with either Karnofsky Performance Status ≤ 50 or Karnofsky Performance Status < 70 with no systemic therapy options do not derive benefit from radiation therapy. Additional information is available at www.asco.org/neurooncology-guidelines .
Arrhythmia Variant Associations and Reclassifications in the eMERGE-III Sequencing Study
Glazer, Andrew M. , Davogustto, Giovanni , Shaffer, Christian M., Desai, Reshma R. , Farber‐Eger, Eric , Dikilitas, Ozan , Shang, Ning , Muhammad, Ayesha , Shaffer, Lauren Lee, Kalash, Olivia R., Bland, Harris T. , Yoneda, Zachary T. , Mitchell, Devyn , Kroncke, Brett M. , Jarvik, Gail P. , Gordon, Allan , Larson, Eric B. , Manolio, Teri A. , Luo, Jonathan Z. , Schaid, Daniel J. , Namjou, Bahram , Singhal, Ashutosh , Liu, Cong , Ralston, James D. , Leppig, Kathleen A. , Håkonarson, Håkon , Sleiman, Patrick , Sohn, Sunghwan , Network, the eMERGE, Denny, Joshua C. , Wei, Wei‐Qi, Shoemaker, M. Benjamin , Roden, Dan M. , Ralston, James D. , Farber-Eger, Eric H , Dikilitas, Ozan , Mosley, Jonathan D , Van Driest, Sara L , Wells, Quinn S , Wada, Yuko , Yoneda, Zachary T , Kroncke, Brett M , Kullo, Iftikhar J , Jarvik, Gail P , Gordon, Adam S , Manolio, Teri A , Mirshahi, Tooraj , Schaid, Daniel, Alsaied, Tarek , Hripcsak, George , McNally, Elizabeth M , Sohn, Sunghwan , Glessner, Joseph , Wei, Wei-Qi , George, Alfred L , Shoemaker, M Benjamin , Roden, Dan M. , Hakonarson, Hakon , Denny, Joshua C , Bland, Sarah T , Liu, Cong , Glazer, Andrew M , Vanoye, Carlos G. , Pacheco, Jennifer A. , Yang, Tao , Driest, Sara L. Van , Wells, Quinn S. , Wada, Yuko , Kullo, Iftikhar J. , Singh, Rajbir , Weng, Chunhua , McNally, Elizabeth M. , Chung, Wendy K. , Carrell, David , Network, the eMERGE, George, Alfred L.

Mayo Clinic

Circulation | December 21, 2021 | Volume: 145 | Issue: 12 | Pages: 877-891

10.1161/circulationaha.121.055562 | PMID 34930020 Get It

Background: Sequencing Mendelian arrhythmia genes in individuals without an indication for arrhythmia genetic testing can identify carriers of pathogenic or likely pathogenic (P/LP) variants. However, the extent to which these variants are associated with clinically meaningful phenotypes before or after return of variant results is unclear. In addition, the majority of discovered variants are currently classified as variants of uncertain significance, limiting clinical actionability. Methods: The eMERGE-III study (Electronic Medical Records and Genomics Phase III) is a multicenter prospective cohort that included 21 846 participants without previous indication for cardiac genetic testing. Participants were sequenced for 109 Mendelian disease genes, including 10 linked to arrhythmia syndromes. Variant carriers were assessed with electronic health record–derived phenotypes and follow-up clinical examination. Selected variants of uncertain significance (n=50) were characterized in vitro with automated electrophysiology experiments in HEK293 cells. Results: As previously reported, 3.0% of participants had P/LP variants in the 109 genes. Herein, we report 120 participants (0.6%) with P/LP arrhythmia variants. Compared with noncarriers, arrhythmia P/LP carriers had a significantly higher burden of arrhythmia phenotypes in their electronic health records. Fifty-four participants had variant results returned. Nineteen of these 54 participants had inherited arrhythmia syndrome diagnoses (primarily long-QT syndrome), and 12 of these 19 diagnoses were made only after variant results were returned (0.05%). After in vitro functional evaluation of 50 variants of uncertain significance, we reclassified 11 variants: 3 to likely benign and 8 to P/LP. Conclusions: Genome sequencing in a large population without indication for arrhythmia genetic testing identified phenotype-positive carriers of variants in congenital arrhythmia syndrome disease genes. As the genomes of large numbers of people are sequenced, the disease risk from rare variants in arrhythmia genes can be assessed by integrating genomic screening, electronic health record phenotypes, and in vitro functional studies. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier; NCT03394859.
De novo coding variants in the AGO1 gene cause a neurodevelopmental disorder with intellectual disability
Schalk, Audrey , Cousin, Margot A. , Dsouza, Nikita R., Challman, Thomas D. , Wain, Karen E. , Powis, Zöe , Minks, Kelly Q., Trimouille, Aurélien , Lasseaux, Eulalie , Michaud, Vincent , Van‐Gils, Julien , Spataro, Nino , Gabau, Elizabeth, Stolerman, Elliot , Washington, Camerun , Louie, Ray, Lanpher, Brendan C. , Kemppainen, Jennifer L., Innes, Micheil, Kooy, R. Frank , Goldenberg, Alice, Lecoquierre, François , Vera, Gabriella , Sheidley, Beth Rosen , Achkar, Christelle Moufawad El , Park, Meredith, Hamdan, Fadi F. , Michaud, Jacques L. , Lewis, Ann J., Zweier, Christiane , Wagner, Matias , Weigand, Heike, Journel, Hubert, Keren, Boris , Passemard, Sandrine , Mignot, Cyril , Brilstra, Eva H. , Itzikowitz, Gina, O’Heir, Emily , Allen, Jake, Donald, Kirsten A. , Korf, Bruce R. , Skelton, Tammi, Rudy, Natasha L. , Dobyns, William B. , Foss, Kimberly , Bosanko, Katherine A. , Alembik, Yves, Durand, Benjamin , Mau‐Them, Frédéric Tran , Ranza, Emmanuelle , Blanc, Xavier , Torti, Erin , Millan, Francisca , Dameron, Amy, Tokita, Mari, Zimmermann, Michael T. , Klee, Eric W. , Piton, Amélie , Gérard, Bénédicte , Ruiz, Anna , Stolerman, Elliot , Kooy, Frank , Lecoquierre, Francois , Reis, André , Wagner, Matias , Passemard, Sandrine , Tran Mau-Them, Frederic , Klee, Eric W , Piton, Amelie , Zimmermann, Michael T , Lacombe, Didier , Angelini, Chloé , Louie, Raymond J. , Meuwissen, Marije E. C. , Goldenberg, Alice , Diderich, Karin E. M. , Reis, André , Gassen, Koen L.I. van , Thompson, Michelle L. , Robin, Nathaniel H. , Zárate, Yuri A. , Antonarakis, Stylianos E. , McWalter, Kirsty

Mayo Clinic

Journal of Medical Genetics | December 20, 2021 | Volume: 59 | Issue: 10 | Pages: 965-975

10.1136/jmedgenet-2021-107751 | PMID 34930816 Get It

Background High-impact pathogenic variants in more than a thousand genes are involved in Mendelian forms of neurodevelopmental disorders (NDD). Methods This study describes the molecular and clinical characterisation of 28 probands with NDD harbouring heterozygous AGO1 coding variants, occurring de novo for all those whose transmission could have been verified (26/28). Results A total of 15 unique variants leading to amino acid changes or deletions were identified: 12 missense variants, two in-frame deletions of one codon, and one canonical splice variant leading to a deletion of two amino acid residues. Recurrently identified variants were present in several unrelated individuals: p.(Phe180del), p.(Leu190Pro), p.(Leu190Arg), p.(Gly199Ser), p.(Val254Ile) and p.(Glu376del). AGO1 encodes the Argonaute 1 protein, which functions in gene-silencing pathways mediated by small non-coding RNAs. Three-dimensional protein structure predictions suggest that these variants might alter the flexibility of the AGO1 linker domains, which likely would impair its function in mRNA processing. Affected individuals present with intellectual disability of varying severity, as well as speech and motor delay, autistic behaviour and additional behavioural manifestations. Conclusion Our study establishes that de novo coding variants in AGO1 are involved in a novel monogenic form of NDD, highly similar to the recently reported AGO2 -related NDD.
Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction
Jackson, Alice M. , Claggett, Brian , Gong, Jianjian , Lefkowitz, Martin, Maggioni, Aldo P. , Martínez, Felipe A. , Pieske, Burkert , Redfield, Margaret M. , Rizkala, Adel R. , Rouleau, Jean L. , Seferović, Petar , Veldhuisen, Dirk J. van , Yılmaz, Mehmet Birhan , Zannad, Faı̈ez , Køber, Lars , Petrie, Mark C. , Solomon, Scott D. , McMurray, John J.V. , McMurray, John J V , Maggioni, Aldo P , Petrie, Mark C , Køber, Lars , Rørth, Rasmus , Liu, Jiankang , Kristensen, Søren Lund , Anand, Inder S. , Cleland, John G.F. , Chopra, Vijay , Desai, Akshay S , Ge, Junbo , Lam, Carolyn S.P. , Packer, Milton , Pfeffer, Marc Alan , Tromp, Jasper , Zile, Michael R. , Jhund, Pardeep S. , Solomon, Scott David

Mayo Clinic

European Journal of Heart Failure | December 17, 2021 | Volume: 24 | Issue: 3 | Pages: 497-509

10.1002/ejhf.2403 | PMID 34918855 Get It

Aim There is an association between heart failure with preserved ejection fraction (HFpEF) and insulin resistance, but less is known about the diabetic continuum, and in particular about pre‐diabetes, in HFpEF. We examined characteristics and outcomes of participants with diabetes or pre‐diabetes in PARAGON‐HF. Methods and results Patients aged ≥50 years with left ventricular ejection fraction ≥45%, structural heart disease and elevated N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) were eligible. Patients were classified according to glycated haemoglobin (HbA1c): (i) normal HbA1c, <6.0%; (ii) pre‐diabetes, 6.0%–6.4%; (iii) diabetes, ≥6.5% or history of diabetes. The primary outcome was a composite of cardiovascular (CV) death and total heart failure hospitalizations (HFH). Of 4796 patients, 50% had diabetes and 18% had pre‐diabetes. Compared to patients with normal HbA1c, patients with pre‐diabetes and diabetes more often were obese, had a history of myocardial infarction and had lower Kansas City Cardiomyopathy Questionnaire scores, while patients with diabetes had more clinical evidence of congestion, but similar NT‐proBNP concentrations. The risks of the primary composite outcome (rate ratio [RR] 1.59, 95% confidence interval [CI] 1.35–1.88), total HFH (RR 1.67, 95% CI 1.39–2.02) and CV death (hazard ratio [HR] 1.35, 95% CI 1.07–1.71) were higher among patients with diabetes, compared to those with normal HbA1c. Patients with pre‐diabetes had a higher risk (which was intermediate between that of patients with diabetes and those with normal HbA1c) of the primary outcome (HR 1.27, 95% CI 1.00–1.60) and HFH (HR 1.35, 95% CI 1.03–1.77), but not of CV death (HR 1.02, 95% CI 0.75–1.40). Patients with diabetes treated with insulin had worse outcomes than those not, and those with ‘lean diabetes’ had similar mortality rates to those with a higher body mass index, but lower rates of HFH. Conclusion Pre‐diabetes is common in patients with HFpEF and is associated with worse clinical status and greater risk of HFH. Clinical Trial Registration: ClinicalTrials.gov Identifier NCT01920711.
7: IMPACT OF FLUID RESUSCITATION IN END-STAGE RENAL DISEASE PATIENTS WITH SEPTIC SHOCK
Chernoby, Katie, Dzingle, Allison, Elefritz, Jessica L. , Doepker, Bruce , Gladden, Dustin, Galyon, Jeffery, Disney, Kathryn, Parker, Jessica , Hoyte, Brittany , Nei, Andrea M. , Patel, Megan Van Berkel

Mayo Clinic

Critical Care Medicine | December 16, 2021 | Volume: 50 | Issue: 1 | Pages: 4-4

10.1097/01.ccm.0000806496.01917.8e Get It